Navigation Links
Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms
Date:3/23/2009

Study Adds to Growing Evidence of B. Infantis 35624 Efficacy in IBS Population

CINCINNATI, March 23 /PRNewswire-FirstCall/ -- A review by researchers at Northwestern University (Chicago, IL) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty. Bifidobacterium infantis 35624 is marketed as Bifantis(R) and can be found in a daily probiotic supplement by Procter & Gamble. The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events. The article was published on the American Journal of Gastroenterology website in advance of appearing in the publication's April 2009 issue(1).

Irritable Bowel Syndrome affects one in five Americans and treatment options are limited. Darren. M Brenner, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study, hypothesized that alterations in gut microflora may contribute to the development of IBS symptoms, and believed these symptoms could be improved by probiotics. "Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS," said Brenner, MD. "After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy."

Clinical evidence and support for Bifantis continues to grow

Bifidobacterium infantis 35624, discovered in the early 1990s by microbiologists at Alimentary Health in Cork, Ireland in partnership with P&G, has been independently tested and evaluated in several clinical trials conducted with humans. This latest review provides continued clinical evidence of Bifantis efficacy in helping to manage a range of gastrointestinal issues including abdominal pain, bloating, constipation, diarrhea, gas and urgency. Bifantis efficacy data has been published or referenced in several medical journals, including the American Journal of Gastroenterology(2), Gastroenterology(3), New England Journal of Medicine(4), Public Library of Science (PLoS)(5) and Nutrition in Clinical Practice(6). Bifantis is found in the number one gastroenterologist recommended probiotic supplement in the United States(7).

Susan Abeln, Principal Scientist at Procter & Gamble, said, "P&G has worked with Alimentary Health to study and develop a supplement with Bifantis because we firmly believe in the benefits of this strain for the millions of Americans struggling to manage digestive upsets each day. We're excited to make Bifantis available to consumers nationwide this spring."

Further credentialing the probiotic strain, P&G recently announced that Bifantis meets the probiotic guidelines established by The International Scientific Association for Probiotics and Prebiotics (ISAPP). These guidelines include five key criteria that consumers should consider when selecting a probiotic product -- strain specificity, clinical proof, packaging, and the quality and quantity of probiotics in a product. Bifantis is proven to fully meet these guidelines, making it a good option for those who want to build and maintain a natural defense against abdominal discomfort and episodic digestive upsets such as constipation, diarrhea, urgency, gas and bloating.

April is National IBS Awareness Month

April is IBS Awareness Month, making this probiotic review timely and appropriate for all IBS sufferers in need of relief. IBS is one of the most common functional bowel disorders diagnosed by primary care physicians and gastroenterologists; and 70 percent of IBS sufferers do not seek medical treatment and continue to suffer from digestive upsets. IBS is second only to the common cold as a leading cause of workplace absenteeism in the U.S. IBS costs the U.S. healthcare system up to an estimated $20 to 25 billion annually in direct and indirect costs.(8)

About Bifantis

Bifantis (Bifidobacterium infantis 35624) is a probiotic strain that can help strengthen the body's natural defenses and play an important role in basic digestion, proper metabolism and overall well-being. Bifantis is the only natural probiotic strain found in Align. Bifantis has clinically demonstrated that, when taken regularly, it can help promote normal digestive health. Capsules containing Bifantis deliver millions of good bacteria to the digestive system to restore intestinal balance and maintain normal digestive health. Visit www.Bifantis.com for more information.

Bifantis was developed by Alimentary Health.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers(R), Tide(R), Ariel(R), Always(R), Whisper(R), Pantene(R), Mach3(R), Bounty(R), Dawn(R) Pringles(R), Folgers(R), Charmin(R), Downy(R), Lenor(R), Iams(R), Crest(R), Oral-B(R), Actonel(R), Duracell(R), Olay(R), Head & Shoulders(R), Wella, Gillette(R), and Braun. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland. Please visit www.alimentaryhealth.ie for more information.

    Contact:     Velvet Gogol Bennett, P&G
    Phone:       (513) 622-4734
    Email:       gogolbennett.vc@pg.com

    Contact:     Chido Tsemunhu, MS&L Worldwide
    Phone:       (212) 468-3681
    Email:       Chido.Tsemunhu@mslworldwide.com



    (1) Am J Gastroenterology advance online publication, 10 March 2009;
    doi: 10.1038/ajg.2009.25
    (2) Whorwell PJ, Altringer I, Morel J, et al, Efficacy of an
    Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with
    Irritable Bowel Syndrome; Am. J Gastroenterology, 2006:101(7): 1581-1590
    (3) O'Mahony L, McCarthy J, Kelly P, et al, Lactobacillus and
    Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and
    Relationships to Cytokine Profiles, Gastroenterology, 2005;128 (3):
    541-551
    (4) E. A. Mayer, M.D., Irritable Bowel Syndrome; N Engl J Med
    2008;358;1692-9
    (5) O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, et al.
    (2008) Commensal-Induced Regulatory T Cells Mediate Protection against
    Pathogen-Stimulated NF-kB Activation. PLoS Pathog 4(8): e1000112.
    doi:10.1371/journal.ppat.1000112
    (6) Arnold Wald and David Rakel; Behavioral and Complementary
    Approaches for the Treatment of Irritable Bowel Syndrome; Nutrition In
    Clinical Practice; 2008:23 (3): 284 - 292
    (7) Among those who recommended a brand of probiotic in 2008, Wolters
    Kulwer survey, 2008
    (8) LadabaumU. Irritable Bowel Syndrome. Adv Stud Med 2004; 4(3):
    128-134; Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA
    Technical Review of Irritable Bowel Syndrome. Gastroenterolgy
    2002;123:2108-2131; Johns Hopkins Resource Center, Digestive Diseases
    Library. Monograph on Irritable Bowel Syndrome (2004).
    www.hopkins-gi.org


'/>"/>
SOURCE Procter & Gamble
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: